LoQus23 Therapeutics Ltd
Entity
Description
  • Value proposition

    Stopping DNA instability; Slowing neurodegenerative disease

    LoQus23 are discovering oral small molecule therapies targeting aberrant DNA mismatch repair to effectively treat Huntington’s and other triplet repeat diseases.

Corporate interactions BETA
Corporate TypeTweets Articles
Novartis
Novartis
Pharmaceutical, Pharmaceutical Manufacturing
Novartis
Pharmaceutical, Pharmaceutical Manufacturing 		Other

30 Sep 2024


Similar entities
Last news
Show all articles
Social network dynamics